Celia Eckert Sells 1,492 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 1,492 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total value of $17,754.80. Following the sale, the senior vice president owned 81,929 shares of the company’s stock, valued at $974,955.10. This trade represents a 1.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Xencor Trading Down 12.4%

Shares of XNCR stock opened at $11.16 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The company has a market capitalization of $818.47 million, a price-to-earnings ratio of -9.00 and a beta of 0.95. Xencor, Inc. has a 52-week low of $6.92 and a 52-week high of $18.69. The company has a 50-day simple moving average of $12.87 and a two-hundred day simple moving average of $12.90.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. The company had revenue of $28.24 million for the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business’s revenue for the quarter was down 46.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.62) EPS. Research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays upped their price target on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Wedbush reiterated an “outperform” rating and set a $26.00 target price on shares of Xencor in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. JPMorgan Chase & Co. cut their price objective on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Finally, Cantor Fitzgerald boosted their target price on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of XNCR. Amalgamated Bank grew its stake in Xencor by 4.8% during the 3rd quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 947 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Xencor by 6.5% during the fourth quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 1,026 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of Xencor by 3.8% in the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock valued at $479,000 after acquiring an additional 1,143 shares in the last quarter. HighVista Strategies LLC lifted its holdings in shares of Xencor by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 1,362 shares during the period. Finally, GAMMA Investing LLC raised its position in Xencor by 77.1% in the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.